Core Viewpoint - A class action lawsuit has been filed against BioAge Labs, Inc. regarding allegations of securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves claims that BioAge and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Shareholders who purchased or acquired BioAge securities during the Class Period have until March 10, 2025, to request to be appointed as Lead Plaintiff [2]. Group 2: Company Events - BioAge conducted its initial public offering (IPO) on September 26, 2024, selling 12.65 million shares at a price of $18.00 per share [3]. - On December 6, 2024, BioAge announced the discontinuation of the STRIDES Phase 2 study of its investigational drug candidate azelaprag due to observed liver transaminitis in some subjects [3]. Group 3: Stock Price Impact - Following the announcement regarding the discontinuation of the study, BioAge's stock price fell by $15.44 per share, representing a decline of 76.85%, closing at $4.65 per share on December 9, 2024 [4].
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioAge Labs, Inc. of Class Action Lawsuit and Upcoming Deadlines - BIOA